Cancer treatment and research communications最新文献

{"title":"Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis","authors":"Marco Galvez-Nino ,&nbsp;Katia Roque ,&nbsp;Rossana Ruiz ,&nbsp;Fernando Namuche ,&nbsp;Victor Paitan ,&nbsp;Tulio Arrese ,&nbsp;Jorge Zegarra ,&nbsp;George Oblitas ,&nbsp;Lisde Gonzalez ,&nbsp;Lorenzo Maco ,&nbsp;Maria del Pilar Cabrera ,&nbsp;Roberto Coello ,&nbsp;Jose Luis Portugal del Pino ,&nbsp;Juan Carlos Ezquerra ,&nbsp;Rodolfo Perez Roca ,&nbsp;Ofelia Coanqui ,&nbsp;Natalia Valdiviezo ,&nbsp;Mivael Olivera ,&nbsp;Tatiana Vidaurre ,&nbsp;Alfredo Aguilar Cartagena ,&nbsp;Luis Mas","doi":"10.1016/j.ctarc.2025.100906","DOIUrl":"10.1016/j.ctarc.2025.100906","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite osimertinib being the standard therapy for advanced EGFR T790M mutation positive NSCLC, in many Latin American countries, access to molecular testing and targeted therapies is limited, directly impacting patient outcomes. This study describes the real-world management and outcomes of Peruvian patients with advanced EGFR-mutated NSCLC who develop the T790M mutation.</div></div><div><h3>Methods</h3><div>We conducted a multicenter retrospective study including patients from nine Peruvian institutions, both public and private, who progressed to first-line EGFR TKI and developed T790M mutation, detected between January 2018 and December 2023. We evaluated demographic, clinico-pathological features and treatment data, including diagnostic pathway, treatment patterns, and survival outcomes.</div></div><div><h3>Results</h3><div>Seventy-eight patients were included; T790M was detected by liquid biopsy in 52.6 % of cases. Median time from progression to T790M detection was 59.5 days (7–244). Osimertinib was administered to 62.8 % of patients after detection, with a median initiation time of 42 days (1–104). Median overall survival (OS) from first-line treatment was 46.6 months for patients who received osimertinib, 23.9 months for those receiving other therapies, and 16.1 months for those without treatment (<em>p</em> = 0.001). Among osimertinib-treated patients, the objective response rate (ORR) was 59.2 %, with a median progression-free survival (PFS) of 15.8 months. Median OS from osimertinib initiation was 16.3 months, significantly longer than for patients receiving other treatments after T790M detection (9.7 months; <em>p</em> = 0.002).</div></div><div><h3>Conclusions</h3><div>This study confirms the real-world effectiveness of osimertinib in Peruvian patients with advanced EGFR T790M positive NSCLC and highlights the importance of timely detection and access to targeted therapies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100906"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain","authors":"Antonio Calles ,&nbsp;Mirian Alonso ,&nbsp;Paloma Martín-Martorell ,&nbsp;Ana Gómez ,&nbsp;Javier de Castro ,&nbsp;Maite Martínez-Aguillo ,&nbsp;Anna Estival ,&nbsp;Joaquin Mosquera ,&nbsp;Natividad Martínez-Banaclocha ,&nbsp;Margarita Majem ,&nbsp;Roxana Reyes ,&nbsp;Eider Azkona ,&nbsp;Ana Laura Ortega ,&nbsp;Santiago Aguin ,&nbsp;Ana Santos ,&nbsp;Andrés Aguilar ,&nbsp;Marc Cucurull ,&nbsp;Ana Blasco ,&nbsp;Virginia Calvo ,&nbsp;Dolores Isla ,&nbsp;Javier Baena","doi":"10.1016/j.ctarc.2025.100905","DOIUrl":"10.1016/j.ctarc.2025.100905","url":null,"abstract":"<div><h3>Background</h3><div>Lorlatinib, a third-generation tyrosine kinase inhibitor (TKI), targets both ALK and ROS1 rearrangements in non-small cell lung cancer (NSCLC). It is approved for ALK-positive patients after progression on prior TKIs but lacks FDA or EMA approval for ROS1-positive NSCLC. This study evaluates lorlatinib's efficacy and safety in both ALK- and ROS1-positive patients through a compassionate use program in Spain.</div></div><div><h3>Methods</h3><div>We analyzed ALK-positive patients treated from November 2016 to February 2019 and ROS1-positive patients treated from November 2016 to March 2021. Eligible patients had Stage IV NSCLC with confirmed ALK or ROS1 rearrangements and prior TKI therapy. For ALK-positive patients, at least two prior TKIs were required if crizotinib was used first. For ROS1-positive patients, prior crizotinib was required.</div></div><div><h3>Results</h3><div>In 61 ALK-positive patients, 59 % had brain metastasis, and 85.2 % received at least two prior ALK TKIs. The overall response rate (ORR) was 32.8 %, with a median progression-free survival (PFS) of 11.2 months. Intracranial ORR was 47.6 %, with higher efficacy in patients with evaluable brain metastasis. In patients with 1, 2, or ≥3 lines of previous TKIs, we observed a median PFS of 15.1, 11.1 and 7.6 months, respectively. Among 42 ROS1-positive patients, 59 % had brain metastasis, and 61.9 % received ≥2 prior therapies. The confirmed ORR was 47.6 %, with 16.7 % complete responses. Median PFS was 10 months. Patients receiving crizotinib alone had a median PFS of 10 months, while those with two prior TKIs had a median PFS of 8.5 months. Intracranial response was 44.4 %, rising to 57.1 % in patients evaluable with brain metastasis. No new safety signals were observed.</div></div><div><h3>Conclusion</h3><div>Lorlatinib demonstrated consistent efficacy and manageable safety in both ALK- and ROS1-positive NSCLC patients treated under the compassionate use program in Spain. These real-world findings support its use as an effective treatment option in heavily pretreated patients.</div></div><div><h3>MicroAbstract</h3><div>We evaluated the efficacy and safety of lorlatinib in <em>ALK</em>- and <em>ROS1</em>-positive NSCLC patients within a compassionate use program in Spain. Among 61 <em>ALK</em>-positive patients, including 59 % with brain metastasis and 85.2 % treated with at least 2 prior ALK TKIs, lorlatinib achieved a confirmed overall response rate (ORR) of 32.8 % and a median progression-free survival (PFS) of 11.2 months. In 42 <em>ROS1</em>-positive patients previously treated with crizotinib, lorlatinib showed an ORR of 47.6 % and a median PFS of 10 months, confirming its clinical activity despite the lack of FDA or EMA approval for this indication.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100905"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunohistological localization of MDM2, MCM2, Fascin, PCNA, EGFR in paraffin section; in the normal and cancerous human ovary","authors":"Mojgan Karimi Zarchi ,&nbsp;Mohammad Ali Khalili ,&nbsp;Fariba Binesh ,&nbsp;Fatemeh Pourhosseini ,&nbsp;Ali Reza Talebi ,&nbsp;Azam Hassanpour ,&nbsp;Mahboubeh Vatanparast","doi":"10.1016/j.ctarc.2025.100932","DOIUrl":"10.1016/j.ctarc.2025.100932","url":null,"abstract":"<div><h3>Background</h3><div>Many protein markers have been investigated in human tissues such as; Fascin, MDM2, MCM2, EGFR, and PCNA. These markers have important physiologic roles in cell proliferation, motility, adhesion, invasion, and survival.</div></div><div><h3>Aims</h3><div>up to date, some researchers focused on these markers in ovarian cancer. However, the mentioned markers have not been investigated in the normal human ovary. Using the immunohistochemical technique we tried to localize these markers in the normal, and cancerous ovarian tissues.</div></div><div><h3>Methods</h3><div>Paraffin-embedded from 10 normal ovarian tissue and 1 case with histologically confirmed ovarian cancer, underwent an immunohistological process, and five mentioned markers were localized in the human ovary. At first, each marker presentation was assessed and then it tried to quantify the amount of presentation.</div></div><div><h3>Results</h3><div>Fascin, PCNA, and MCM2 are presented high in the normal ovarian tissue, while EGFR is restricted to the epithelium and very rarely in the granulosa cells. Also, MDM2 was negative for all normal ovaries. All markers had overexpression in ovarian cancer in different patterns.</div></div><div><h3>Conclusion</h3><div>Ovarian cancer tissue showed over-expression of the cell proliferation and motility markers compared with the normal ovary. These markers may have prognostic value in ovarian cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100932"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143891721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the impact of energy, radiation type, and concentration on dose enhancement by Gold Nanoparticles","authors":"Wrya Parwaie ,&nbsp;Mikaeil Molazadeh ,&nbsp;Tohid Mortezazadeh","doi":"10.1016/j.ctarc.2025.100933","DOIUrl":"10.1016/j.ctarc.2025.100933","url":null,"abstract":"<div><div>This study aimed to investigate the radiosensitization effects of Gold Nanoparticles (GNPs) on microscopic and macroscopic Dose Enhancement Ratios (DER) across various radiation energies and types, as well as different GNP concentrations. We utilized the OncoSeed ¹²⁵I model with 6711 spectra, simulating linac megavoltage beams to irradiate GNP-loaded cells. Ten-nanometer GNPs filled small water cells (30 cm per side) in a cubic phantom, while additional 10 nm GNPs were placed in cubic voxels (0.1 × 0.1 × 0.1 µm³) centered in a 1 cm diameter cell, with concentrations ranging from 0 to 30 mg/g of Au were used to study the Dose Enhancement Factor (DEF). Both elastic and inelastic scattering mechanisms were included to accurately model low- and high-energy radiations. A monoenergetic beam of 50 keV targeted the GNP-loaded tumors, with interaction physics managed using data from the ENDF/BIII.1 file. Our findings revealed significant radiosensitization effects, particularly with low-energy and short-range electrons (&lt;1 µm). DEF values ranged from 1 to 30 mg/g of gold under a 50 keV photon beam, resulting in dose increases of up to 2.29 for photons and 1.22 for electrons. We observed a 100 % reduction in DEF for electrons at the same energy and concentration, while higher ratios were noted for the linac photon beam. The modeled ¹²⁵I seed produced a dose rate of 0.965 ± 0.002 cGy h^-1 U^-1, consistent with findings from the TG-43 report and existing literature. Increasing radiation energy significantly decreased DER, while higher GNP concentrations resulted in a dramatic increase. Further research on this topic is strongly encouraged.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100933"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143898478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between p53 protein and ER, PR status in breast cancer tissue","authors":"Fang Zhang","doi":"10.1016/j.ctarc.2025.100895","DOIUrl":"10.1016/j.ctarc.2025.100895","url":null,"abstract":"<div><div>The aim of the present study was to investigate the protein expression levels of p53 in breast cancer tissues and analyze the relationship between the increased protein expression levels of p53 and the status of the estrogen receptor (ER) and progesterone receptor (PR). A total of 137 patients with breast cancer admitted to the General Surgery Department of the People's Liberation Army General Hospital from June to October 2023 were selected for inclusion in the present study and the expression levels of p53, ER and PR in cancer tissues were detected using immunohistochemistry. According to postoperative pathological results, patients were divided into ER positive negative groups and PR positive negative groups. Chi-squared tests used to analyze the difference in the protein expression levels of p53 between the ER positive and negative groups and the PR positive and negative groups. Additionally, the relationship between the protein expression levels of p53 in breast cancer tissue with patient age, the longest tumor diameter, tumor TNM stage, axillary lymph node status and histological subtype were analyzed. The protein expression levels of p53 in the ER positive and negative groups was 38.27 and 66.07 %, respectively, and the difference was statistically significant.The protein expression levels of p53 in the PR positive and negative groups was 42.27 and 67.50 %, respectively, and the difference was statistically significant. The protein expression levels of p53 in breast cancer tissue was not significantly associated with patient age, the longest tumor diameter, tumor TNM stage and histological subtype. But it was related to the status of axillary lymph nodes, the difference was statistically significant. In conclusion, the protein expression levels of p53 in breast cancer tissues were negatively correlated with the expression of ER and PR, which could be used to potentially provide clinical guidance for the prognosis of patients with breast cancer and improve the diagnosis and treatment of these patients in the future.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100895"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143641667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidermal growth factor receptor specific immunotherapy for SHH medulloblastoma tested in an in vitro blood-brain barrier-model","authors":"Christina Krüger ,&nbsp;Petros Paplomatas ,&nbsp;Naomé Kreuter ,&nbsp;Malte Hellwig ,&nbsp;Alicia Eckhardt ,&nbsp;Christian Conze ,&nbsp;Leticia Oliveira-Ferrer ,&nbsp;Jacqueline Tischendorf ,&nbsp;Vanessa Thaden ,&nbsp;Ulrich Schüller ,&nbsp;Judith Niesen","doi":"10.1016/j.ctarc.2025.100950","DOIUrl":"10.1016/j.ctarc.2025.100950","url":null,"abstract":"<div><div>Despite advances in treating pediatric malignant tumors like SHH-medulloblastoma (SHH-MB), the current standard of care remains surgery followed by chemo- and radiotherapy. This aggressive therapy goes along with a significant morbidity with many long-term side effects, especially in children and adolescents. Therefore, more targeted therapies are urgently needed. Immunotoxins (ITs) conjugated to tumor-antigen specific antibodies have shown potential for selectively targeting tumor cells. In this study, we generated a single chain variable fragment (scFv)-based IT that incorporates a truncated, less immunogenic variant of <em>Pseudomonas</em> Exotoxin A (ETA'). The IT specifically targets the epidermal growth factor receptor (EGFR), a tumor-associated antigen commonly overexpressed in SHH-MB. Wecould demonstrate that this immunotherapeutic approach reduces tumor cell viability and induces apoptosis in MB-cell lines with IC₅₀ values ranging from 3.1 to 17.5 nM. Given that SHH-MB exhibit dysregulated PI3-kinase (PI3K) pathway signaling, we combined the IT with a PI3K inhibitor. Combination treatment led to dose-dependent reductions in IC₅₀ values (from 2.51 – 13.9 nM at 0.5 µM start concentration to 1.01 – 3.4 nM at 2 µM start concentration). Additionally, we could demonstrate that the generated IT can successfully cross the blood-brain barrier (BBB) <em>in vitro</em> in an <em>in vitro</em> BBB-model based on human brain microvascular endothelial (HBMEC) cells . These results suggest that this immunotherapeutic approach is a promising candidate for further development and clinical application.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100950"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and pathological differences between early- and late-onset colorectal cancer and determinants of one-year all-cause mortality among advanced-stage patients: a retrospective cohort study in Medellín, Colombia","authors":"Álvaro Esteban Ruiz Grajales ,&nbsp;Manuela María Orozco Puerta ,&nbsp;Senshuang Zheng ,&nbsp;Geertruida H. de Bock ,&nbsp;Juan Camilo Correa Cote ,&nbsp;Esteban Castrillón Martínez","doi":"10.1016/j.ctarc.2024.100797","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100797","url":null,"abstract":"<div><h3>Objective</h3><p>To identify the differences between early- (EOCRC) and late-onset colorectal cancer (LOCRC), and to evaluate the determinants of one-year all-cause mortality among advanced-stage patients.</p></div><div><h3>Methods</h3><p>A retrospective cohort study was carried out. CRC patients ≥ 18 years old were included. Chi-Square test was applied to compare both groups. Uni- and multivariate regressions were performed to evaluate the determinants of one-year all-cause mortality in all advanced-stage patients regardless of age of onset.</p></div><div><h3>Results</h3><p>A total of 416 patients were enrolled; 53.1 % were female. Ninety cases (21.6 %) had EOCRC and 326 (78.4 %) had LOCRC. EOCRC cases were predominantly sporadic (88.9 %). Histology of carcinoma other than adenocarcinoma (<em>p</em> <em>=</em> 0.044) and rectum tumors (<em>p</em> <em>=</em> 0.039) were more prevalent in EOCRC. LOCRC patients were more likely to have smoking history <em>(p</em> &lt; 0.001) and right colon tumors (<em>p</em> = 0.039). Alcohol consumption history (odds ratio [OR]: 3.375, 95 %CI: 1.022–11.150) and stage IV (OR: 12.632, 95 %CI: 3.506–45.513) were associated with higher one-year all-cause mortality among advanced-stage patients, the opposite was noted with left colon tumors (OR: 0.045, 95 %CI: 0.003–0.588).</p></div><div><h3>Conclusion</h3><p>EOCRC was predominantly sporadic and had more cases of uncommon histological subtypes and rectal tumors. LOCRC was characterized by a higher prevalence of smoking history. Multivariate regression revealed an association between higher one-year all-cause mortality and alcohol consumption history and stage IV in advanced-stage patients. CRC exhibited differences based on age of onset. The evaluated factors associated with CRC mortality provide valuable insights for healthcare professionals, emphasizing the importance of adequate clinical assessment and early CRC diagnosis.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100797"},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000091/pdfft?md5=6da1553e1727aa40e30c374c36841037&pid=1-s2.0-S2468294224000091-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139744024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invited commentary on “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study”","authors":"","doi":"10.1016/j.ctarc.2024.100806","DOIUrl":"10.1016/j.ctarc.2024.100806","url":null,"abstract":"<div><p>The article “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study” have presented the experience of AVD chemotherapy regimen in newly diagnosed Hodgkin's lymphoma (HL) in a single center in Brazil. Though being a small retrospective study, results from this study have provided the medical community a real-world data on HL in Brazil. ABVD has remained the standard of care for patients of newly diagnosed HL both in early and advance stages. Newer targeted molecules have also come for use in novel combinations with existing drugs. However, in a situation of temporary scarcity of bleomycin due to lack of supply during 2017 in Brazil led to use of incomplete ABVD regimen without bleomycin, i.e. AVD for HL. However, Soldi et al. utilized the opportunity to retrospectively study if the omission of bleomycin leads to subnormal treatment or unwarranted effects.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100806"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000182/pdfft?md5=cdb30affa96b38910d56529090f337a3&pid=1-s2.0-S2468294224000182-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcopenia in gastric cancer and its impact on early postoperative outcome","authors":"Mira Sudam Wagh ,&nbsp;Arun K. Balan ,&nbsp;Arun Peter Mathew ,&nbsp;C.A. Rakesh ,&nbsp;Jagath Krishna ,&nbsp;K. Chandramohan ,&nbsp;Madhu Muralee","doi":"10.1016/j.ctarc.2024.100829","DOIUrl":"10.1016/j.ctarc.2024.100829","url":null,"abstract":"<div><h3>Background</h3><p>Sarcopenia, defined as progressive and generalised loss of skeletal muscle mass, quality, and strength, is considered as a poor prognostic factor in cancer. Outcomes in oncology mainly focus on survival related to disease and treatment. Other factors affecting the end result get less attention. This study was conducted with the aim to determine presence of sarcopenia in operable gastric cancer, factors positively correlating with presence of sarcopenia and its impact on early postoperative outcomes.</p></div><div><h3>Methodology</h3><p>This is a prospective study conducted from January 2020 to December 2021 in a tertiary care cancer hospital. All patients with adenocarcinoma stomach planned for curative intent surgery were assessed for sarcopenia by measuring hand grip strength(HGS) and skeletal muscle index(SMI). Comparison was made between patient and tumour related factors in patients with and without sarcopenia and impact of sarcopenia on early postoperative outcome was assessed.</p></div><div><h3>Results</h3><p>74 patients were assessed for sarcopenia. 32 (43.2 %) were patients diagnosed with sarcopenia. Advanced age(<em>p</em> = 0.040), low BMI (<em>p</em> &lt; 0.001), gastric outlet obstruction (<em>p</em> = 0.020) and urgent surgery (<em>p</em> = 0.002) positively correlated with sarcopenia. Curative resection was done in 68(91.89 %) patients and these patients were evaluated for early postoperative outcomes. 18 (26.5 %) patients had complications of Clavien Dindo grade 3 or above. Sarcopenia was not significantly associated with major postoperative complications(<em>p</em> = 0.857).</p></div><div><h3>Conclusion</h3><p>Sarcopenia, though associated with a substantial proportion of patients with gastric cancer, does not significantly affect early postoperative complications in a high volume oncology centre .</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100829"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000418/pdfft?md5=2072b55a4a18ef912b997cd606da6570&pid=1-s2.0-S2468294224000418-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low to intermediate grade lung neuroendocrine tumours. A single centre real world experience","authors":"Jacqueline Martin ,&nbsp;Mohammad Alrehaili ,&nbsp;Horia Marginean ,&nbsp;Rachel Goodwin ,&nbsp;Paul Wheatley-Price","doi":"10.1016/j.ctarc.2024.100846","DOIUrl":"10.1016/j.ctarc.2024.100846","url":null,"abstract":"<div><h3>Introduction</h3><div>Lung neuroendocrine tumours (LNETs) are a rare heterogenous group of tumours whose incidence has been increasing. We investigated the diagnosis, treatment, and survival patterns of patients with low to intermediate grade LNETs.</div></div><div><h3>Methods</h3><div>A retrospective chart review of patients with low to intermediate grade LNETs, treated at a Canadian tertiary-level cancer centre was performed.</div></div><div><h3>Results</h3><div>We identified 59 patients. Most were G1or G2 and well or moderately differentiated. Forty-seven patients presented with local or locally advanced disease, of which 57.4 % received curative intent surgery. The rest were treated with definitive radiation, radical chemoradiation with platinum and etoposide, palliative chemotherapy with doxorubicin, or supportive care. The five-year overall survival (OS) for those treated surgically was 83 % versus 44 % in the non-surgical group. Metastatic disease was seen in 24/59 patients, with a five-year OS in patients with stage IV disease of 39 %. Of those with advanced or unresectable disease (<em>n</em> = 32), 21 received palliative systemic treatment with up to three lines of therapy. First-line treatment was most commonly chemotherapy with platinum/etoposide combination or somatostatin analogue therapy. Second-line treatment involved chemotherapy or targeted everolimus. PRRT was used once as a first-line and once as second-line therapy. Third-line included lanreotide or chemotherapy with capecitabine/temozolomide combination.</div></div><div><h3>Conclusion</h3><div>Overall, patients with surgically resectable disease had a good five-year OS. However, inoperable or more advanced disease was associated with a poorer OS. Despite many treatment options, the sequence of treatments is poorly established. This highlights the need for further development and dissemination of evidence-based guidelines for LNET patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100846"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}